@article {IWASE1297, author = {H. IWASE and M. SHIMADA and T. TSUZUKI and Y. HORIUCHI and S. KUMADA and J HARUTA and T. YAMAGUCHI and M SUGIHARA and K INA and K. KUSUGAMI and S. GOTO}, title = {A Phase II Multicentric Trial of S-1 Combined with 24 h-infusion of Cisplatin in Patients with Advanced Gastric Cancer}, volume = {25}, number = {2B}, pages = {1297--1301}, year = {2005}, publisher = {International Institute of Anticancer Research}, abstract = {Background: The aim of this multicentric trial was to determine the clinical toxicities and antitumor effects of a chemotherapy regimen of S-1 combined with cisplatin in patients with inoperable locally or metastatic advanced gastric cancer. Patients and Methods: Forty-two patients were entered into the study. S-1 (80 mg/m2) was administered orally daily for 14 consecutive days and 24-h infusion of cisplatin (70 mg/m2) was administered on day 8 of every 28-day cycle. Results: The overall response rate was 50\% and complete response rate was 5\%. The most common adverse event was leucopenia, which occurred with grade 3 in 7 patients (16.6\%) and grade 4 in 2 patients (4.8\%). Non-hematological adverse events were generally mild. The median survival time was 342 days. The 2-year survival rate was 22.9\%. Conclusion: This combination chemotherapy is active, convenient and well tolerated in patients with high-grade advanced gastric cancer. Copyright{\textcopyright} 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/25/2B/1297}, eprint = {https://ar.iiarjournals.org/content/25/2B/1297.full.pdf}, journal = {Anticancer Research} }